drugset / Trial / NCT03373409
Safety and Pharmacokinetics of Halix(TM) Albuterol Unit Dose Disposable Inhaler Versus Albuterol MDI
Phase 1
Completed
12 enrolled
Concentrx Pharmaceuticals, Inc.
Kramer Consulting, LLC · collabPharPoint Research, Inc. · collab
RandomizedCrossoverOpen-labelTreatment
Summary
Healthy male and female volunteers without asthma will be recruited to enroll in a single dose 3-way crossover study of the safety and pharmacokinetics of albuterol when administered using the Halix (TM) albuterol unit dose disposable dry powder inhaler (DPI) and the albuterol HFA (hydrofluoroalkane) MDI inhaler.
Timeline
- Start
- 2017-11-30
- Primary completion
- 2018-05-28
- Completion
- 2018-07-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Salbutamol | Unknown | 90 ug | Inhaled |
| Subject | Salbutamol | Unknown | 180 ug | Inhaled |